Business Wire

Flowchem Strengthens Leadership Team, Appointing COO, Technology Team, and Board of Senior Industry Experts

13.2.2025 13:00:00 CET | Business Wire | Press release

Share

Flowchem (“Flowchem” or the “Company”) and SCFPartners (“SCF”) are pleased to announce several personnel additions. Flowchem is a leading global player in the drag reducing agent (“DRA”) market, providing custom-engineered specialty chemicals to help customers around the world optimize the performance of their infrastructure. These key appointments bolster the already-strong management team in place at the time of the Company’s acquisition in 2024, positioning it for continued growth and industry leadership.

  • Shivali Agarwal has been appointed as Chief Operating Officer (“COO”). Shivali brings decades of industry operating experience in roles across the globe, most recently serving as Group General Manager, Production Systems at SLB (NYSE:SLB). Shivali holds a Master of Business Administration from Harvard Business School and a Master of Science in Biological Sciences and a Bachelor of Science in Chemical Engineering from the Birla Institute of Technology & Science, Pilani, India.

  • Flowchem has bolstered its technology team with several key technical hires, significantly enhancing its product development capabilities. Dr. Lu-Chien Chou is a recognized leader in the field who has led cutting-edge DRA research at Baker Hughes (NASDAQ:BKR) and other DRA providers. John Stephens joins Flowchem after decades of experience in industrial chemical research and development and manufacturing, including at Siege Engineering and PPG Industries (NYSE:PPG). These scientific leaders ensure that Flowchem remains at the forefront of DRA technology while maintaining its industry-leading quality and performance in reducing costs and emissions for customers across multiple product lines.

  • The Company has assembled a best-in-class Board of Directors of senior industry leaders with energy and chemicals experience:

    • Cris Gaut (Chairman) – Chairman and former CEO, Forum Energy Technologies (NYSE:FET); former CFO, Halliburton (NYSE:HAL); former CFO and Co-President, Ensco International

    • Joe Blount – former President and CEO, Colonial Pipeline; former CEO, Century Midstream LLC; former Chair of the Association of Oil Pipe Lines (AOPL)

    • Scott Rogan – CFO, Eagle LNG Partners; former SVP, Targa Resources; former Partner and head of midstream investing, Energy Capital Partners

    • Chris Oversby – former CEO, Optum Energy Solutions, a DRA technology business; former chemicals executive at Baker Hughes, Clariant & Univar

    • Sean Rice – Managing Partner, SCF Partners

    • Dan West – Managing Director, SCF Partners

Flowchem's CEO, Jon Blair, commented, “I am pleased to announce the appointment of Shivali Agarwal to COO. Shivali is a tremendous leader with a proven track record of success, and her operational expertise will enhance our efforts going forward. Our strengthened technology team and strategic board of directors will also be instrumental in improving our DRA solutions and enhancing the value we provide to our customers worldwide.”

Dan West, Managing Director at SCF Partners, stated, “Our team at Flowchem has demonstrated significant success in creating value for both customers and shareholders by making infrastructure operations safer, more efficient, and less emissions-intensive. We are excited to add these key leaders to reinforce and accelerate the company’s growth.”

About Flowchem, Val-Tex, and Sealweld

Flowchem is a leading supplier of Drag Reducing Agents (“DRA”) which optimize pipeline flow and increase throughput capacity. Use of Flowchem DRA enables infrastructure operators across the globe to reduce energy consumed in pumping operations, which in turn reduces both costs and associated greenhouse gas emissions and maximizes overall profitability of infrastructure operations. Flowchem provides flow consultation and turnkey solutions for pipeline applications worldwide. For more information, please visit www.flowchem-dra.com.

Val-Tex, founded in 1962, is one of the industry’s premier providers of high-quality valve maintenance products such as sealants, lubricants, fittings, and injection equipment. Val-Tex’s longstanding commitment to product excellence and customer satisfaction has earned the trust and recommendation of the world’s leading valve manufacturers. To learn more, please visit www.valtex.com.

Sealweld has provided superior valve care products and services since 1969, with a focus on the safe reduction and elimination of pipeline valve leakage. Decades of experience and development of practical solutions have resulted in high-performing valve care products equally suited to either gas or liquid pipelines. For more information, visit www.sealweld.com.

About SCF Partners

Founded in 1989, SCF provides equity capital and strategic growth assistance to build and grow leading energy service, equipment, and technology companies that operate throughout the world. SCF has invested in more than 80 platform companies and made more than 400 additional acquisitions to develop 18 publicly listed energy service and equipment companies over its history. The firm is headquartered in Houston, Texas, and has offices in Calgary, Aberdeen, and Australia. For more information, please visit www.scfpartners.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250210052408/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye